Introduction
The invention of minimally invasive glucose sensors with subcutaneous placement has allowed people with diabetes to continuously monitor changes in glucose levels. Continuous glucose monitoring (CGM) provides the opportunity to obtain and maintain good glycemic control by limiting the frequency and intensity of glucose excursions. Of particular importance, CGM may limit hypoglycemia over the long term;
1-3 hypoglycemia has been identified as a major barrier to attaining optimal glucose control among insulin-treated patients with diabetes. 1, [4] [5] [6] In addition, warning alarms can help individuals to be aware of impending periods of hyperglycemia or hypoglycemia prior to the onset of major symptoms. 3 However, CGM is still an emerging field, and the accuracy of approved CGM systems has been reported to be suboptimal; [7] [8] [9] thus there remains a need for the continued development and improvement in CGM technology.
A CGM system with a novel sensor insertion device is currently under development. This system employs electrochemical sensor technology by generating an electrical signal proportional to the interstitial glucose concentration using glucose oxidase. The system is intended to be portable and has three main components: a sensor that is inserted subcutaneously without the use of a trocar or needle, a transmitter that adheres to the skin and relays the electrical signals from the sensor, and a receiver that can be worn on a belt or placed nearby (within 10 ft) that records the electrical data and can convert the signals to glucose concentrations. This study evaluated the performance of a prototype of this CGM system for measuring glucose during different glycemic levels, with an emphasis on hypoglycemia through the induction of two hypoglycemic states in each subject.
Methods

Subjects
Adults aged 18 to 65 years with type 1 or type 2 diabetes were screened for study eligibility. Subjects were required to be otherwise healthy and to have a body mass index of 19 to 35 kg/m 2 and a hemoglobin A1c (HbA1c) less than or equal to 12%. Exclusion criteria included any acute diseases, chronic diseases other than diabetes; skin disorders; or current use or recent exposure to topical medications at the sensor insertion site or to medications that, in the opinion of the investigator, might interfere with the investigational device or the subject's ability to participate in the study; pregnancy; or current or recent alcohol or drug abuse. In addition, ingesting acetaminophen within 24 h of the study procedure was a criterion for rescheduling. The study protocol was approved by an institutional review board (Schulman Associates IRB, Inc., Cincinnati, OH), and all subjects completed the informed consent process.
Study Design
This was a single-center, glucose clamp study consisting of hypoglycemic, euglycemic, and hyperglycemic plateaus as well as transition periods of rapidly changing glucose levels. The main components of the CGM system used in this study included the sensor module with sterile electrodes, an attached transmitter, and a receiver. The CGM sensors were near-final design; however, other parts of the system were early prototype and not representative of the final product design.
The sensors have electrodes made from platinum and silver/silver chloride with an outer membrane composed of polyurethane and are 0.33 mm in diameter. The sensors were inserted into the subcutaneous tissue on each side of the subject's abdomen (two sensors per subject) on the evening prior to the glucose clamp procedure. A length of approximately 12 mm of the sensor was inserted at approximately a 30° angle and a depth of 5 to 6 mm beneath the skin. Two sensors were inserted for each subject in order to maximize the amount of data collected per subject; comparison between sensors was not a prespecified end point in this early feasibility study, and the results from each sensor were analyzed independently. Subjects were allowed to consume water throughout the study but were to remain fasting after the provided evening meal.
On the study day (i.e., morning after sensor insertion), the subject's current insulin treatment was stopped, and blood glucose was established and maintained at the target level (90 mg/dl) by an automated glucose clamp device (Biostator CGIIS ® , MTB Medizintechnik, Amstetten, Germany). In addition to the glucose infusion provided by the Biostator, a variable intravenous insulin infusion was applied in order to clamp glucose at four 40 min plateau periods: first hypoglycemic period (50 mg/dl), hyperglycemic period (250 mg/dl), second hypoglycemic period (50 mg/dl), and euglycemic period (90 mg/dl).
Transition periods between each plateau were managed such that blood glucose was rapidly changing at an approximate rate of 2 mg/dl/min (Figure 1 ). Glucose and/or insulin were infused to achieve and maintain each plateau period. At the conclusion of the testing period and after the subject was stable at a euglycemic glucose level of 90 mg/dl for at least 40 min, both sensors were removed.
Data Collection
Raw electrical current values were collected once every minute from the CGM system and converted to values representative of sensor interstitial fluid glucose concentrations. The conversion was done retrospectively, after the study was completed, using a predetermined algorithm. A Yellow Springs Instruments (YSI) glucose analyzer (YSI Life Sciences, Inc., Yellow Springs, OH) was used for the measurement of venous plasma samples collected every 5 min, and results were regarded as reference measurements. The CGM system was calibrated once per CGM sensor, just prior to the initiation of the clamp procedure (i.e., just before the transition from "steady state" to the first hypoglycemic plateau). Calibration was done retrospectively using a YSI plasma glucose measurement in conjunction with a preset algorithm that was determined prior to study initiation.
Accuracy
The absolute percent difference (APD) from the YSI reference value, which describes the point accuracy of the CGM, was calculated as APD = |CGM -YSI| × 100, YSI where CGM represents a glucose reading from the investigational CGM device and YSI is the corresponding reference value. In order to compensate for the delay between blood and interstitial fluid glucose, the algorithm compares a YSI value with a CGM value obtained 4 min later. [10] [11] [12] [13] [14] The absolute rate difference (ARD), which describes the rate-of-change accuracy of the CGM device, was calculated as
where CGM' t and YSI' t are the glucose rates of change of the CGM and YSI devices, respectively, over 5 min.
Three types of error grid analysis (EGA) were performed, including point-wise EGA [Parkes (consensus) 15 and Clarke 16 EGA classify results based on the clinical significance of data from a single point in time], rate Figure 1 . Study design. Representative glucose levels achieved during the clamp procedure with a targeted rate of change of 2 mg/dl/min; the actual rate of glucose change varied among subjects depending on each individual's status, including insulin sensitivity and difficulties in changing glucose levels between glycemic states (e.g., hypoglycemic to hyperglycemic).
EGA (classifies results based on the clinical significance of differences in glucose rates of change between devices), and continuous EGA (combines rate EGA and Clarke EGA and takes into account where the CGM result would be on the grid at a later time, calculated from the rate of change of CGM glucose).
Safety
Adverse events were recorded throughout the study. Subjects underwent physical examination and vital sign measurements (blood pressure, pulse, aural temperature) after sensor removal. The sensor explant sites were evaluated for edema and erythema using the Draize scoring system 17, 18 approximately 5 min following removal of the two sensors. Follow-up assessments were conducted 3 to 7 days after the procedure, including an assessment of adverse event reporting, a review of concomitant medications, and an examination of the sensor explant sites.
Results
Subjects
Of 23 screened subjects, 15 met the inclusion and exclusion criteria and 14 completed the study; 1 subject who qualified for enrollment served as a backup and did not complete the study. One subject withdrew consent, and 3 subjects did not meet inclusion criteria (no evidence of diabetes, n = 1; HbA1c ≥12%, n = 2). The remaining reasons for exclusion were based on safety of the clamp procedure (retinopathy and hypertension, n = 1; history of epilepsy, n = 1; high uric acid, n = 1; low hemoglobin and hematocrit, n = 1). Subject demographic and baseline characteristics are shown in Table 1 . Half of the subjects had type 1 diabetes, and half had type 2 diabetes.
Sensor Insertion
Sensor insertion into the abdomen was successful on the first attempt for 25 of 28 sensors (89.3%). For the remaining three sensors, a repeated attempt to insert the sensor was required.
Accuracy of the CGM Sensor
The smallest APDs for the plateau periods were observed during the hypoglycemic plateaus ( Table 2 ). The smallest APDs and ARDs for the transition periods were observed during the euglycemic to hypoglycemic transition (steady state to first plateau; Table 3 ).
Parkes (consensus) EGA for the four plateau periods combined (n = 873 paired data sets) showed that 86.8% of results were in zone A (accurate) compared with YSI reference glucose values (Figure 2) . The grouped outlier shown at the 100 mg/dl level was data collected from a single sensor. An additional 12.1% of results were in zone B, indicating that they differed from the YSI values but were associated with benign or no treatment error. Only 1% of results were in zone C (associated with clinically significant error), and no results were within zones D or E (associated with increasing clinically significant error). Similar results were observed with the Clarke EGA (zone A, 79.8%; zone B, 14.9%; zone D, 5.3%).
Rate EGA showed that the majority (88.6%) of the transition period results were in zones A (68.6%) and B (20.0%) and categorized as accurate or benign compared with YSI reference values, while 11.5% were in zones C (3.8%), D (5.3%), or E (2.4%; Figure 3 and Table 4 ). Continuous EGA indicated that 91.0% of CGM results were associated with accurate (83.2%) or benign (7.8%) errors, and the CGM system was most accurate in the Rate EGA (transition periods). Results were classified based on the clinical significance of the differences in glucose rates of change between the CGM and YSI devices (zone A R , accurate; zones lB R and uB R , benign or no treatment error; zones lC R , uC R , lD R , uD R , lE R , and uE R , increasing clinically significant error). u, upper; l, lower. (Figure 4) . During the hypoglycemic transition period, 81.7% of CGM results were in the accurate (79.3%) or benign (2.4%) error zones, whereas 18.3% were associated with erroneous results.
Data Loss
The algorithm used for CGM data analysis was designed to withhold or cease data transmission under certain predefined circumstances, such as high or low current values outside the physiologic range or unrecoverable changes (e.g., dislodged or unstable sensor, electrical short). No data were lost because of reception failures. Data withheld because of the algorithm resulted in a loss of 3.9% of total minutes (recording time). An additional 5.0% of total minutes were lost because the algorithm indicated that two sensors required replacement during the study. The first sensor replacement was triggered because of low current during the first hypoglycemic period, and the second sensor replacement was triggered because of a high current during the hyperglycemic period. especially during the hypoglycemic plateaus (mean APDs of 12% and 14%). Dynamic accuracy during the transition periods was also good, with an overall mean ARD of 1.1 mg/dl/min. Point-wise, rate, and continuous EGA classified a high proportion of results as accurate or benign/no treatment error (98.9%, 88.6%, and 91.0%, respectively).
The high level of accuracy in the hypoglycemic range observed with this CGM system is of interest, considering some of the accuracy limitations of currently available CGM devices, particularly at low glycemic levels. [7] [8] [9] 21 In an early comparative study evaluating the accuracy (based on continuous EGA) of two CGM devices, the Medtronic MiniMed CGM system and Abbott FreeStyle Navigator ® had similar accuracy over the euglycemic range (89.3% and 88.8%, respectively) but not during hypoglycemia, with the latter CGM device having significantly greater accuracy in this state (61.6% and 82.4%, respectively; p < .0005). 21 Later, a study of the Medtronic Guardian ® REAL-time CGM system in an intensive care unit setting found that less than 50% of readings in the hypoglycemic range were accurate. 7 In another study, the clinical utility of self-monitoring of blood glucose in the hypoglycemic range significantly exceeded that of CGM using the FreeStyle Navigator; based on continuous EGA, 83.5%, 6.4%, and 10.1% of self-monitoring of blood glucose readings and 57.1%, 8.4%, and 34.5% of CGM results were classified as "clinically accurate," "benign errors," and "clinical errors," respectively (all p < .0001). 8 Finally, in a study assessing the accuracy of the DexCom SEVEN ® CGM system, the mean APD was shown to be 16.7% across all glucose concentrations and 24.3% in the hypoglycemic range, with continuous EGA showing a reduction in accuracy from 97.5% in the euglycemic range to 75.0% in the hypoglycemic range. 22 The investigational CGM system assessed in this study was safe and well tolerated, with only mild non-devicerelated adverse events reported during the study. The longterm safety and tolerability of this CGM system remain to be established.
Because of the retrospective nature of this early feasibility study, additional studies are needed to evaluate the accuracy of this CGM system in the clinical setting. Also, since CGM devices are intended to be routinely worn by patients in their daily lives, it will also be important for future analyses to determine the accuracy of the CGM sensors after several days of continuous use and under a wide variety of conditions. 
Safety
Five subjects experienced a total of six adverse events during the study ( Table 5 ). All six events were classified as nonserious, mild, and unlikely to be related to the CGM device. There were no sensor fractures during the study. Based on skin assessments, one subject experienced erythema at the sensor explant sites, with a score of 2 (well-defined erythema) on the day of sensor explant; all other cases were scored as 0 (no erythema) or 1 (very slight erythema). At the follow-up visit 3 to 7 days after sensor explant, all scores for erythema were 0. No subjects experienced edema during the study.
Discussion
Application of CGM technology to diabetes care is still a relatively new field, and currently available CGM systems must overcome several challenges. 9, 19, 20 There are accuracy concerns specific to CGM systems that are related to measuring glucose concentration in the interstitial fluid. 9, 19, 20 Given the time delay of glucose transport from blood to the interstitial space (lag time) and the difference in circulating versus interstitial glucose concentrations, CGM systems require proper calibration using direct blood glucose measurements. 9, 19, 20 Additionally, the CGM system must have a broad range of performance, including excellent performance at both the lower and upper limits of the glycemic range.
In this study, a prototype, investigational CGM system was associated with a high degree of accuracy with a glucose clamp during hypoglycemic, euglycemic, and hyperglycemic plateaus. The point accuracy of the CGM system was very good during the plateau periods,
